Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
0
Authors
Linda‐Gail Bekker
Linda‐Gail Bekker•Moupali Das•Flavia Kiweewa
Published
July 24, 2024
Abstract
There are gaps in uptake of, adherence to, and persistence in the use of preexposure prophylaxis for human immunodeficiency virus (HIV) prevention among cisgender women.
